The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations

Abstract Due to recent advances in the treatment of hypercholesterolemia, low density lipoprotein (LDL) cholesterol concentrations below 2.6 mmol/l have become attainable. In general, LDL cholesterol is determined indirectly according to Friedewald. We examined the performance of the Friedewald formula at low concentrations of LDL cholesterol in comparison with a β-quantification method. We analyzed 176 samples from individuals treated by LDL apheresis with a mean LDL cholesterol concentration of 3.07 mmol/l and found that the Friedewald formula underestimated LDL cholesterol with a bias of −18.5%, −14.5%, −7.3%, and −3.8% at mean LDL cholesterol levels of 1.58, 2.4, 3.49, and 4.67 mmol/l, respectively. Thus, the lower the LDL cholesterol concentration was, the greater the negative bias. We conclude that the Friedewald formula may not be reliable at low LDL cholesterol concentrations produced by LDL apheresis. This finding may also be of relevance to the monitoring of patients being treated with lipid lowering drugs.

[1]  N. Rifai,et al.  Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. , 2000, Clinical chemistry.

[2]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[3]  W. März,et al.  Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). , 1999, The American journal of cardiology.

[4]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[5]  J. Pincus Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[6]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[7]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[8]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[9]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[10]  W. Kleophas,et al.  LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. , 2008, Artificial organs.

[11]  S. MacMahon,et al.  Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis. , 1997, Clinical chemistry.

[12]  Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[13]  A. von Eckardstein,et al.  Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. , 1997, Clinical chemistry.

[14]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[15]  E. Rimm,et al.  Analytical performance and clinical utility of a direct LDL-cholesterol assay in a hyperlipidemic pediatric population. , 1996, Clinical chemistry.

[16]  T. Bosch Low-density lipoprotein hemoperfusion using a modified polyacrylate adsorber: in vitro, ex vivo, and first clinical results. , 1996, Artificial organs.

[17]  M Nauck,et al.  Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. , 1995, Clinical chemistry.

[18]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[19]  P. Bachorik,et al.  National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. , 1995, Clinical chemistry.

[20]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[21]  L. Wilkins National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .

[22]  J. Joven,et al.  Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. , 1994, Clinical chemistry.

[23]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[24]  M. Sentí,et al.  Calculated Low-Density Lipoprotein Cholesterol Should Not Be Used for Management of Lipoprotein Abnormalities in Patients With Diabetes Mellitus , 1993, Diabetes Care.

[25]  N. Rifai,et al.  Current recommendations of the Adult Treatment Panel and the Children and Adolescents Treatment Panel of the National Cholesterol Education , 2004 .

[26]  C. Wanner,et al.  Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. , 1991, Kidney international.

[27]  J. Joven,et al.  Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. , 1990, The New England journal of medicine.

[28]  P. Wilson,et al.  Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. , 1990, Clinical chemistry.

[29]  G. R. Warnick,et al.  Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. , 1990, Clinical chemistry.

[30]  E. DeLong,et al.  A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. , 1986 .

[31]  W. März,et al.  Analysis of plasma lipoproteins by ultracentrifugation in a new fixed angle rotor: evaluation of a phosphotungstic acid/MgCl2 precipitation and a quantitative lipoprotein electrophoresis assay. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[32]  W Bablok,et al.  Comparison of Several Regression Procedures for Method Comparison Studies and Determination of Sample Sizes Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II , 1984, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[33]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.